Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.44 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.44 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9199185 | 1.00 | CYSLTR2 (0.51) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL10224774 | 0.84 | CYSLTR1 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL9203800 | 0.84 | PLA2G2A (0.50) | — | |
| SCHEMBL9203804 | 0.84 | PLA2G2A (0.50) | — | |
| SCHEMBL201960 | 0.84 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL201961 | 0.84 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL30497375 | 0.84 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL29517073 | 0.84 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL9119729 | 0.83 | CYSLTR1 (0.51) | CYSLTR2CYSLTR1 | |
| SCHEMBL9119725 | 0.83 | CYSLTR1 (0.51) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829716-B2 | decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast | Synthon Pharmaceuticals, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829716-B2 | decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast | Synthon Pharmaceuticals, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7786138-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2010-08-31 | — | — | US | disclosed |
| US-7786138-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2010-08-31 | — | — | US | disclosed |
| US-20100099879-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | BENOVSKY PETR | 2010-04-22 | — | — | US | disclosed |
| US-20100099879-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | BENOVSKY PETR | 2010-04-22 | — | — | US | disclosed |
| US-7601741-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2009-10-13 | — | — | US | disclosed |
| US-20090093636-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | BENOVSKY PETR | 2009-04-09 | — | — | US | disclosed |
| US-20090093636-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | BENOVSKY PETR | 2009-04-09 | — | — | US | disclosed |
| US-7476748-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2009-01-13 | — | — | US | disclosed |
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| WO-2007057227-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007057225-A2 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007057228-A1 | A NEW INTERMEDIATE FOR MAKING MONTELUKAST AND RELATED COMPOUNDS | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
| EP-0399818-B1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC (CA) | 1995-08-16 | — | — | EP | disclosed |
| US-5204358-A | Antiallergens; antiinflammatory agents; treatment of asthma, rhinitis, bronchitis and skin diseases | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| US-5104882-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-04-14 | — | — | US | disclosed |
| EP-0399818-A1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC. (CA) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | LTC4S, LTA4H, CYSLTR1 | CYSLTR2 10/4885CYSLTR1 3/4885PTGER1 64/4885 |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CYP4A11, CYP51A1, CYP4F11 | CYSLTR2 19/4885CYSLTR1 9/4885PTGER1 83/4885 |
| US-20090093636-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CYP4A11, CYP51A1, CYP4F11 | CYSLTR2 19/4885CYSLTR1 9/4885PTGER1 83/4885 |
| US-20100099879-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CMA1, CYP51A1, NOTUM | CYSLTR2 11/4885CYSLTR1 5/4885PTGER1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.